| Literature DB >> 28919998 |
Francesca Mion1, Stefania Vetrano2,3, Silvia Tonon1, Viviana Valeri1, Andrea Piontini3, Alessia Burocchi4, Luciana Petti5, Barbara Frossi1, Alessandro Gulino6, Claudio Tripodo6, Mario P Colombo4, Carlo E Pucillo1.
Abstract
One of the most fascinating aspects of the immune system is its dynamism, meant as the ability to change and readapt according to the organism needs. Following an insult, we assist to the spontaneous organization of different immune cells which cooperate, locally and at distance, to build up an appropriate response. Throughout tumor progression, adaptations within the systemic tumor environment, or macroenvironment, result in the promotion of tumor growth, tumor invasion and metastasis to distal organs, but also to dramatic changes in the activity and composition of the immune system. In this work, we show the changes of the B-cell arm of the immune system following tumor progression in the ApcMin/+ model of colorectal cancer. Tumor macroenvironment leads to an increased proportion of total and IL-10-competent B cells in draining LNs while activates a differentiation route that leads to the expansion of IgA+ lymphocytes in the spleen and peritoneum. Importantly, serum IgA levels were significantly higher in ApcMin/+ than Wt mice. The peculiar involvement of IgA response in the adenomatous transformation had correlates in the gut-mucosal compartment where IgA-positive elements increased from normal mucosa to areas of low grade dysplasia while decreasing upon overt carcinomatous transformation. Altogether, our findings provide a snapshot of the tumor education of B lymphocytes in the ApcMin/+ model of colorectal cancer. Understanding how tumor macroenvironment affects the differentiation, function and distribution of B lymphocytes is pivotal to the generation of specific therapies, targeted to switching B cells to an anti-, rather than pro-, tumoral phenotype.Entities:
Keywords: ApcMin/+ mice; B lymphocytes; IL-10; IgA; intestinal cancer
Year: 2017 PMID: 28919998 PMCID: PMC5593718 DOI: 10.1080/2162402X.2017.1336593
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110